Nebraska Clinics Offer Experimental Pancreatic Cancer Drug Helping Former Sen. Ben Sasse
Two Nebraska cancer centers are offering an FDA-pending pancreatic drug through expanded access, partly spotlighted by Ben Sasse's diagnosis.
An experimental pancreatic cancer drug that former U.S. Senator Ben Sasse is using to treat his stage 4 diagnosis is now available to patients at two Nebraska institutions — Nebraska Cancer Specialists and the Fred & Pamela Buffett Cancer Center — through an expanded access program while the drug remains under FDA review. Expanded access programs, sometimes called 'compassionate use,' allow patients to receive investigational drugs outside of clinical trials before the FDA has formally approved them. The two Nebraska centers are participating in such a program, meaning patients in the region can now access the same treatment Sasse has publicly credited with helping him. Sasse, the former Republican senator from Nebraska who later served as president of the University of Florida before stepping down, disclosed his stage 4 pancreatic cancer diagnosis and spoke about it in a CNN interview with Jake Tapper, where he also reflected on personal regrets. Stage 4 pancreatic cancer is among the most serious cancer diagnoses, with historically low survival rates. The local availability of the drug marks a concrete development for Nebraska patients who might otherwise lack access to cutting-edge treatments still working through the federal approval process.
Why it matters
Pancreatic cancer is one of the deadliest cancers, and expanded access programs can be a critical lifeline for patients who have exhausted standard options. The program's availability in Nebraska means patients outside of major research hubs may now reach a treatment that was previously inaccessible.
What's next
The drug's broader availability will depend on the FDA's ongoing review and whether it ultimately receives formal approval.
Key facts
- Nebraska Cancer Specialists and the Fred & Pamela Buffett Cancer Center are both participating in the expanded access program
- The drug is still under FDA review and has not yet received formal approval
- Former Sen. Ben Sasse has a stage 4 pancreatic cancer diagnosis
- Sasse discussed his diagnosis and personal regrets in a CNN interview with Jake Tapper
- Expanded access programs allow use of investigational drugs outside clinical trials for seriously ill patients
Bias & framing notes
The Journal Star and Star Herald ran essentially identical reporting focused on the medical and local-access angle of the story. The Mirror focused on Sasse's personal interview and emotional reflections, emphasizing his regrets rather than the drug access development. The human-interest framing in The Mirror diverges noticeably from the public health angle of the Nebraska outlets, though no sources directly contradict each other on facts.
NewsClear — neutral news & congressional tracking · Bill of the Week